Daily Roundup

NEU.ASX SDV.ASX MYE.ASX EQR.ASX LNW.ASX

Neuren Pharmaceuticals is riding high on strong momentum for its flagship drug DAYBUE. The company reported record Q2 sales of US$125 million, marking a solid 30% jump from the same period last year. The real driver here is DAYBUE STIX, a new powder formulation that's resonating with patients—by the end of Q2, roughly 40% of all US DAYBUE patients were already using it. Looking ahead, Neuren expects a European launch in Q4 2026 following a positive recommendation from regulators in June, while Japan trial results are anticipated to land sometime between September and November. The company also pocketed US$12.9 million in royalty income during the quarter, with upgraded guidance suggesting even more royalties to come based on updated sales projections.

SciDev is making its first real push into the data centre space. The company has landed initial contracts with two of Australia's largest hyperscale data centre operators, covering design, consulting, and embedded engineering services. While the revenue contribution is modest for now—around $0.5 million expected in the first half of FY27—management sees room for these contracts to expand down the track.

Mastermyne Group (trading as Metarock Group) has secured a major mining services contract worth up to $255 million. The deal with GM3 covers the Dendrobium underground coal mine in New South Wales and kicks off with an initial two-year term valued at approximately $85 million. Two additional two-year extension options are available, which would push the total value to $255 million over six years. The contract will create more than 140 new jobs and builds on Mastermyne's existing operations at the site. The company enters FY27 with a strengthened order book, buoyed by sustained demand for specialist underground coal mining services.

EQ Resources, a global tungsten producer, hit a new revenue record in July with A$51 million, powered by a 36% surge in production compared to June. The company pumped out 14,255 mtu and achieved an impressive average realised price of US$2,386 per mtu. The Barruecopardo site was particularly strong, posting its highest monthly production since December 2025 with a 48% increase, while Mt Carbine also chipped in with a 16% production bump.

Light & Wonder wrapped up Q2 2026 with results that showed steady progress across the board. Consolidated revenue came in at $828 million, up 2% year-over-year, while the real standout was net income, which jumped 26% to $120 million. Adjusted EBITDA climbed 9% to $383 million, driven by strength in Gaming and iGaming operations. Recurring revenue grew 6% to $580 million, and the company generated $156 million in adjusted free cash flow—a 50% increase from the prior year. Management returned $134 million to shareholders through buybacks and maintained its full-year outlook for mid- to high-single-digit AEBITDA growth. The company remains focused on deleveraging, aiming to bring its net debt ratio below 3.0x during the first half of 2027.